Announcements Trials
Browse Landscape

Status

Completed 710Recruiting 268Unknown 249Terminated 175Active not recruiting 137Withdrawn 56Not yet recruiting 55Enrolling by invitation 12Suspended 3No longer available 2Available 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Expanded_access 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Multiple Myeloma 20Melanoma 16Prostatic Neoplasms 15Neoplasms 15Recurrence 13Carcinoma, Non-Small-Cell Lung 13Leukemia, Myeloid, Acute 12Glioblastoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma 8Breast Neoplasms 7Sarcoma 6Neuroblastoma 6Lung Neoplasms 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia 6Glioma 6Pancreatic Neoplasms 5Lymphoma, Non-Hodgkin 5Lambert-Eaton Myasthenic Syndrome 5Gastrointestinal Stromal Tumors 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Neuroendocrine Tumors 4Liver Neoplasms 4Hodgkin Disease 4Carcinoma, Renal Cell 4Precancerous Conditions 3Pheochromocytoma 3

Interventions

neratinib 1bemarituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
No longer available × Urinary Bladder Neoplasms × Clear all
NCT03801278 2021-12-13

FPA144

Five Prime Therapeutics, Inc.

No longer available
Genitourinary

Urinary Bladder Neoplasms

NCT01956253 2017-03-14

Single Subject Neratinib in Bladder Cancer (NRR)

UNC Lineberger Comprehensive Cancer Center

No longer available
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡